Page last updated: 2024-12-07

nitrobenzylthioinosine 5'-monophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitrobenzylthioinosine 5'-monophosphate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID119116
MeSH IDM0091279

Synonyms (9)

Synonym
6-s-((4-nitrophenyl)methyl)-6-thio-5'-inosinic acid
nitrobenzylthioinosine 5'-monophosphate
65199-10-2
9h-purine, 6-(((4-nitrophenyl)methyl)thio)-9-(5-o-phosphono-beta-d-ribofuranosyl)-
5'-inosinic acid, 6-s-((4-nitrophenyl)methyl)-6-thio-
6-{[(4-nitrophenyl)methyl]sulfanyl}-9-(5-o-phosphonopentofuranosyl)-9h-purine
DTXSID20983780
((2r,3s,4r,5r)-3,4-dihydroxy-5-(6-((4-nitrobenzyl)thio)-9h-purin-9-yl)tetrahydrofuran-2-yl)methyl dihydrogen phosphate
{[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-{[(4-nitrophenyl)methyl]sulfanyl}-9h-purin-9-yl)oxolan-2-yl]methoxy}phosphonic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The combination was also more toxic to the mice but the inclusion of nitrobenzylthioinosinate in the therapy significantly alleviated the toxicity of the drug combination."( Effect of nitrobenzylthioinosinate on the toxicity of tubercidin and ethidium against Trypanosoma gambiense.
Ikediobi, CO; Ogbunude, PO, 1982
)
0.26

Pharmacokinetics

ExcerptReferenceRelevance
" NBMPR-P and other inhibitors of nucleoside transport may have therapeutic applications in manipulation of the pharmacokinetic behavior and toxicity of nucleoside drugs."( Modification by nitrobenzylthioinosine-5'-monophosphate of pseudoisocytidine pharmacokinetics in mice and rats through inhibition of membrane transport.
Chou, TC; Kolassa, N; Paterson, AR, 1983
)
0.27

Compound-Compound Interactions

ExcerptReferenceRelevance
" Mice receiving the combination of tubercidin (or nebularine) plus NBMPR-P or dilazep, as well as those that survived the combination with dipyridamole, appeared healthy and were found to have normal size livers and spleens."( Treatment of schistosomiasis by purine nucleoside analogues in combination with nucleoside transport inhibitors.
Cha, S; el Kouni, MH; Messier, NJ, 1987
)
0.27

Dosage Studied

ExcerptRelevanceReference
" The therapeutic effect was optimal at dosage levels of the protecting agent in excess of those required in nonleukemic mice for protection against the lethal nebularine dosages used, suggesting that the therapeutic effect was due to the joint presence in the leukemic cells of a metabolite of NBMPR-P and nebularine; NBMPR-P protection of the leukemic host against nebularine lethality was necessary for the therapeutic effect to be manifested."( Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5'-monophosphate.
Lynch, TP; Paran, JH; Paterson, AR, 1981
)
0.5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (45.16)18.7374
1990's9 (29.03)18.2507
2000's6 (19.35)29.6817
2010's1 (3.23)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.71 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other32 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]